An image of a person is shown with attention drawn to fat accumulated in his liver, a feature of the liver disease non-alcoholic steatohepatitis (NASH). Next to the person is a blue circle with an image of a liver with kisspeptin hormone receptors depicted on the surface of the liver and arrows pointing downward to indicate a decrease in fatty liver and NASH. 

liver-sex-hormone

An image of a person is shown with attention drawn to fat accumulated in their liver, a feature of the liver disease, non-alcoholic steatohepatitis (NASH). Next to the person is a blue circle with an image of a liver inside of it with kisspeptin hormone receptors depicted on the surface of the liver and arrows pointing downward to indicate a decrease in fatty liver and NASH. 

Rutgers University scientists who investigated the role of kisspeptin in liver disease stand together in a laboratory.

liver-group

Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.

A sex hormone may help reverse liver damage

News

Anthony Samir is an expert in ultrasound imaging for liver disease at Harvard Medical School.

Stephen Williams is the Chief Medical Officer at SomaLogic.

08242021-somalogic19ga

istock-1322425857-1800x900

Sophie Cazanave is a NASH researcher at Glympse Bio.

21017-glympse-websitestillsv3-proteaseinbloodvial

Wendy Winkler is the Chief Scientific Officer at Glympse Bio.

A close up view of a vial of blood is pictured with peptides of different length floating in it. These peptides may be indicative of fatty liver disease.

wendy

SomaLogic scientists work in the lab to develop protein-based diagnostic tests for NASH.

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.

Goodbye biopsies, non-invasive diagnostics for fatty liver disease are here

liver

Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients

Grading non-alcoholic steatohepatitis

Articles

AI is put to work on NASH biomarkers

iBiopsy study shows promise in diagnosing severity of disease in patients

Liver

Transcriptome sequencing of patients with liver disease reveals gene expression changes that could help to track disease severity and progression

A new angle on NAFLD

Owlstone study pinpoints limonene for early diagnosis of NASH and NAFLD

A promising biomarker for diagnosing liver disease

1-0325-cover

March 2025

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.  

untitled-design-2025-03-12t163253-386

cn-bio-logo-colour-300mm

CN Bio

Discover how researchers leverage microphysiological systems in toxicology studies. &nbsp;

Harnessing liver-on-a-chip models for drug safety

Webinars

A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

78041-1800x900-2

Thermo Fisher Scientific

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.

Enhancing bioanalytical studies with centralized data management

Whitepaper

A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

untitled-design-2025-03-11t120646-259

takara-bio-inc-logo-vector

Takara Bio

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.

NAFLD